August 24, 2024 – August 25, 2024
Managing Metabolic Disorders Pharmacy CE Conference
(16 hrs. CPE)

August 24, 2024 – August 25, 2024
Managing Metabolic Disorders Pharmacy CE Conference
(16 hrs. CPE)

$300.00

ACCREDITATION

iCARE Pharmacy Services, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is an ACPE application-based* and knowledge-based activity. Participants may receive up to 16 hours of CPE credit by attending sessions and successfully completing the continuing pharmacy education (CPE) activity evaluation.

iCARE Pharmacy Services, Inc. is approved by the Florida Board of Pharmacy as a provider of continuing pharmacy education.

DISCLOSURES

Speakers have no relevant conflict of interests nor financial relationships.  All persons in a position to control the content of this activity have declared that no conflict of interest exists for this activity.

TARGET AUDIENCE

Pharmacists and Pharmacy Technicians of all practice backgrounds.

CANCELLATION POLICY
Participants must submit cancellations in writing. Participants will receive a credit for a future CPE program.

ZOOM WEBINAR INFORMATION
Participants may join via any electronic device. Be sure to have downloaded the ZOOM software in advance to avoid any delays. You will be able to see the speakers and their presentations. You will be able to respond to speaker learning assessments via the CHAT Feature and ask questions via the Q&A Feature.

Description

Saturday, August 24, 2024

Beyond Insulin: Advancements in Type 1 Diabetes Care                                  

8:00-9:30am Consultant/General

Jasmine B. R. Cutler, Pharm.D., CPh, Assistant Professor, Dept of Pharmacotherapeutics and Clinical Research, USF Health Taneja College of Pharmacy, University of South Florida

Upon completion of this activity, pharmacists will be able to: Discuss the pathophysiology, clinical presentation, and risk factors of diabetes; Explain the differences between Type 1 and Type 2 diabetes; Discuss available treatment options for Type 1 diabetes; Demonstrate proper insulin administration; Discuss blood glucose monitoring and management of hypoglycemia and hyperglycemia; Introduce emerging therapies and technologies used in the treatment of diabetes, specifically Type 1 diabetes; Discuss the financial implications of Type 1 diabetes and available resources to address patient concerns and questions; Highlight lifestyle management of Type 1 diabetes; Apply learned concepts about Type 1 diabetes to a patient case.

UAN: 0675-0000-24-021-L01-P*

 

Rethinking and Reframing Obesity Management               9:30-11:00am Consultant/General

Marile Santamarina, PharmD, CPh, CDE, CPT, Sr. Medical Science Liaison, Immunology, Fresenius Kabi USA

Upon completion of this activity, pharmacists will be able to: Identify obesity as a chronic disease; Review the challenges of anti-obesity drug development; Discuss clinical practice guidelines for the management of obesity.

UAN: 0675-0000-24-022-L01-P

 

A New Era in the Management of Type 2 Diabetes              

11:15-12:45pm Consultant/General

Marile Santamarina, PharmD, CPh, CDE, CPT, Sr. Medical Science Liaison, Immunology, Fresenius Kabi USA

Upon completion of this activity, pharmacists will be able to: Provide an overview of complex pathophysiology of Type 2 Diabetes (T2D); Review change progression in the American Diabetes Association Clinical Practice Guidelines from 2018 through 2024; Discuss the clinical positioning of newer drug classes in the management of type 2 diabetes; Recommendation clinical decisions using patient practice cases.

UAN: 0675-0000-24-023-L01-P

 

Critical Importance of Lowering LDL-C and Applying Lipid Guidelines

12:45-2:15pm Consultant/General

Ana M. Alvarez, PharmD, CPh, LCC, Senior Medical Science Liaison, Cardiovascular, Novo Nordisk, Inc

Upon completion of this activity, pharmacists will be able to: Correlate the relationship between plasma lipids and coronary heart disease; Defend the rationale for drug selection among various classes of drugs used to reduce cholesterol; Integrate guideline-recommended strategies for lowering LDL-C in primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD); Develop evidence-based treatment plan for patients with elevated LDL-C.

UAN: 0675-0000-24-024-L01-P*
 

Mitigation and Prevention of Medication Errors in Pharmacy Practice

2:30-4:30pm General

Norman P. Tomaka, BS Pharm, MS, CPh, FAPhA, Clinical Consultant Pharmacist, Consultant Pharmacy Services

Upon completion of this activity, pharmacists will be able to:  Recognize statutory responsibilities that foster ongoing pharmacy regulatory compliance; Recognize recurring medication errors; Describe quality improvement regulations for pharmacies licensed in Florida; Define elements of a proactive Continuous Quality Improvement process that promotes ongoing quality; Discuss the use of Root Cause Analysis(RCA) to enhance quality pharmacy services and prevent errors; Describe the implementation of an action plan to improve overall pharmacy practice quality and mitigate medication errors; Demonstrate enactment of procedures that promote ongoing patient safety in pharmacy practice.

UAN: 0675-0000-24-025-L05-P

 

Sunday, August 25, 2024

Updates in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Out With the Old in With the New

8:00-9:30am Consultant/General

Erenie Guirguis, Pharm. D., BCPS, FFSHP, Associate Professor of Pharmacy Practice, PGY-1 Residency Program Director, Lloyd L. Gregory School of Pharmacy

Upon completion of this activity, pharmacists will be able to: Discuss the nomenclature change from NAFLD to MASLD to increase disease awareness; Recognize the associated burden of disease due to MASLD in adult patients; Discuss the pathophysiology and clinical presentation of MASLD; Review current national guideline recommendations for the treatment of patients with MASLD; Evaluate recent literature on emerging treatment options and the real-world application for the management of MASLD patients.

UAN: 0675-0000-24-026-L01-P*

 

Navigating Hypertension Management                                   9:30-11:00am Consultant/General

Yasmin Grace, B.S., PharmD, Professor of Pharmacy Practice, Palm Beach Atlantic University

Upon completion of this activity, pharmacists will be able to: List factors contributing to the etiology of primary and secondary hypertension; Describe the diagnosis of hypertension and the purpose of ambulatory blood pressure monitoring; Recommend lifestyle modifications for hypertension management and evaluate their efficacy; Describe the current approach to the management of hypertension; Compare and contrast the characteristics of antihypertensive drug classes including place in therapy, adverse effects, drug interactions, contraindications, and monitoring; Design individualized antihypertensive treatment regimens for different patient populations.

UAN: 0675-0000-24-027-L01-P*

 

From Filtration to Precision: Evolving CKD Therapies

11:15-12:45pm Consultant/General

Erini Serag-Bolos, PharmD, Assistant Dean of Academic Affairs, Associate Professor, Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, Department of Internal Medicine, Morsani College of Medicine

Upon completion of this activity, pharmacists will be able to: Interpret laboratory values of chronic kidney disease (CKD); Develop prevention and treatment plans for patients with metabolic CKD; Discuss medications that may cause CKD and/or require renal dose adjustments.

UAN: 0675-0000-24-028-L01-P*

 

Managing Metabolic Disorders – The Role of the Pharmacist within the Technological Ecosystem                

12:45-2:15pm Consultant/General

Aimon C. Miranda, PharmD, BCPS, Associate Professor, Coordinator of Clinical Informatics, Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, Department of Internal Medicine I College of Medicine, University of South Florida and Kevin Olson

Upon completion of this activity, pharmacists will be able to: Define how the technological ecosystem interacts with individuals and organizations; Describe current applications for managing metabolic disorders; Discuss barriers and implications of technology integration.

UAN: 0675-0000-24-029-L01-P

 

Validation and Counseling of Prescriptions for Controlled Substance & Opioids

2:30-4:30pm General

Joseph Cammilleri, PharmD, BCACP, CPE, Ambulatory Care Clinical Pharmacist, Pain Management, PGY2 Pain/Palliative Care Program Director, UF Health.

Upon completion of this activity, pharmacists will be able to: Describe how to ensure access to controlled substances for all patients with a valid prescription; Use the Prescription Drug Monitoring Program’s Database; Assess prescriptions for appropriate therapeutic value; Detect prescriptions that are not based on a legitimate medical purpose; Discuss the laws and rules related to the prescribing and dispensing of controlled substances; Discuss proper patient storage and disposal of controlled substances; Discuss protocols for addressing and resolving problems recognized during the drug utilization review; Provide education on section 381.887, F.S., emergency treatment for suspected opioid overdoses and on the State Surgeon General’s Statewide Standing Order for Naloxone; Counsel patients with opioid prescriptions; Provide available treatment resources for opioid physical dependence, addiction, misuse, or abuse.

UAN: 0675-0000-24-030-L08-P*